- 1
- 2
Jean Baptiste FREY
|
|
|
Midi Capital is a rapidly growing independent private equity company, specialized in financing small and medium businesses. |
||
MIDI CAPITAL
Investment ManagerDiana P Friedman
Henry Schein, Inc. is the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners. The Company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. A Fortune 500® Company and a member of the S&P 500® and NASDAQ 100® Indexes, Henry Schein employs more than 18,000 Team Schein Members and serves more than one million customers.
The Company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 100,000 branded products and Henry Schein private-brand products in stock, as well as more than 150,000 additional products available as special-order items. The Company also offers its customers exclusive, innovative technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services.
Headquartered in Melville, N.Y., Henry Schein has operations or affiliates in 30 countries. The Company's sales reached a record $10.4 billion in 2014, and have grown at a compound annual rate of approximately 16 percent since Henry Schein became a public company in 1995.
For more information, visit the Henry Schein website at www.henryschein.com
Guillaume FROGET
CNS-Neurology
Dermatology
Gastroenterology / Hepatology
Nutrition and Weight Loss
Obstetrics/Gynecology (Women's Health)
Pediatrics/Neonatology
Pulmonary/Respiratory Diseases
Psychiatry/Psychology
Rheumatology
Your innovative solution
Porsolt, a long established, AAALAC accredited and fully GLP compliant, preclinical CRO, has been providing efficacy evaluation and safety pharmacology services for over 30 years, covering the drug development process from early screening thru regulatory submission.
Porsolt provides physiopathological models in multiples species, customized procedures, and tailored solutions, (including in vitro assays and drug formulation analysis and bioanalytical services), for psychiatric and neurological disorders, pain, cardiac and vascular diseases, metabolic and eating disorders, and dermatology.
Pharmaceutical companies / Biotechs / Fondations / Academia
Science-based / GLP compliance / tailored solutions / flexibility
PORSOLT
Chief Executive Officer & PresidentPhil Frost MD
OPKO Health, Inc. is a multi-national pharmaceutical and diagnostics company that aims to establish industry-leading positions in large and rapidly growing medical markets by leveraging our discovery, development, and commercialization expertise and our novel and proprietary technologies. We intend to leverage our global commercialization expertise to pursue acquisitions of commercial businesses that will both drive our growth and provide geographically diverse sales and distribution opportunities. We have and may continue to make investments in other early stage companies that we perceive to have valuable proprietary technology and significant potential to create value for OPKO as a shareholder.
Our Focus is on Point-of-Care and Novel Molecular Diagnostics, Proprietary Pharmaceuticals, and Vaccines. Since 2009, OPKO has completed five national and international acquisitions contributing to its technology and commercial operations.
OPKO continues to explore acquisition opportunities for complementary pharmaceuticals, compounds, technologies, and businesses. We expect our future growth to arise from leveraging our proprietary technology, development strengths, and pursuit of complementary and strategic acquisitions and investments.
Pharmaceutical and Diagnostic Products, Medical Devices
OPKO Health
Chairman and CEOMr Les Funtleyder
E Squared Capital is an accomplished fund targeting emerging growth companies with potentially disruptive technologies or services. Founded in 2009, our flexible approach and team of seasoned professionals has particular expertise in finding unique solutions for public and private companies to accelerate growth, and significantly enhance shareholder valuation in a wide array of industries.
Our strategy includes not only investing our partners' capital, but sourcing capital from third parties. We support out investments with capital market advice and we develop creative solutions for companies seeking financing and operational expertise. These alliances offer unique access for company executives to better build and grow their businesses in an effective, strategic and thoughtful manner.